JP2002087965A - In-mouth disintegrable aspirin-containing tablet - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide aspirin-containing tablets easily takeable even without using water because of being quickly disintegrable and liquefiable in the mouth and therefore valuably usable as easy-to-chew tablets or in-mouth disintegrable tablets such as troches. SOLUTION: The in-mouth disintegrable aspirin-containing tablets are characterized by comprising (A) aspirin, (B) an antacid and (C) at least one compound selected from monosaccharides, disaccharides and sugar alcohols.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a tablet containing aspirin and an antacid (hereinafter referred to as a buffered aspirin tablet), and more particularly to a tablet containing orally disintegrating aspirin used as a orally disintegrating pharmaceutical tablet.

[0002]

2. Description of the Related Art Conventionally, a tablet-type internal medicine containing aspirin has been generally taken with water. However, there are problems such as difficulty in swallowing depending on the shape, size, etc. of the tablet, and a dosage form that does not require water for ingestion is also desired. In recent years, such as chewable tablets (chewable tablets), A tablet-type oral medicine to be chewed and taken has been developed.

[0003] Generally, aspirin-containing oral tablets have a certain strength to prevent vibration, friction when worn in a glass bottle or a resin container, abrasion / damage of tablets due to collision, and cracking when taken out of PTP packaging. However, in the case of oral tablets of the type such as the above-mentioned chewable tablet, it is difficult to chew if the strength and hardness are high. In particular, the ability to chew tablets (ease of chewing) is an important requirement for children with developing teeth and elderly people who cannot chew sufficiently.

[0004] As a means for improving such ingestibility, tablets that can be rapidly disintegrated in the mouth can be considered. The following method is exemplified as a known means for increasing disintegration.

That is, after a powder containing a solvent is tabletted into tablets, the solvent is removed to form voids, thereby facilitating saliva invasion and facilitating disintegration (JP-A-10-1679).
No. 58, JP-A-9-48726, JP-A-8-2910
No. 51) has been proposed. However, in this method, there is a limit to the solvent that can be selected based on the difference in the solubility of the active ingredient and the agent to be taken internally, and there are other problems such as poor moldability in a wet state, and voids are formed. for,
The strength was not satisfactory. In addition, there is a problem of having complicated steps such as solvent addition, dispersion, and solvent removal.

A method has been proposed in which crystalline cellulose and low-substituted hydroxypropylcellulose are blended at a predetermined ratio (Japanese Patent Application Laid-Open No. 9-71523). However, tablets obtained by this method have a problem in stability that the disintegration time is greatly affected by the tableting pressure or the disintegration time is delayed with time.

[0007] Further, a method of granulating a sugar having a low moldability with a sugar having a good moldability (WO95 / 20380) has been proposed. However, this method has a disadvantage that a tableting failure is likely to occur. Then, a method of blending an oily component (Japanese Patent Application Laid-Open No. 8-333242) has been proposed, but the tablets obtained by this method are not satisfactory in disintegration time and have problems in terms of stability. is there. In addition, a method of adding an amino acid or a salt thereof (Japanese Patent Application Laid-Open No. 8-208520) has been proposed, but the use of this method is extremely limited due to concerns about interaction with a drug.

[0008] As described above, the conventional methods have problems, and among buffered aspirin-containing tablets, buffered aspirin tablets are particularly satisfactory because the disintegration delay by tableting is remarkable. No tablets having strength, hardness and disintegration properties were obtained.

Therefore, there has been a demand for a good chewable tablet type buffered aspirin tablet which simultaneously satisfies strength, hardness and disintegration.

[0010]

DISCLOSURE OF THE INVENTION The present invention has been made in view of the above circumstances, and maintains the strength and hardness required for tablets, and disintegrates quickly in the mouth, and is easy to chew or requires chewing. An object of the present invention is to provide an orally disintegrating aspirin-containing tablet suitable as a novel buffered aspirin tablet that is easy to take.

[0011]

Means for Solving the Problems and Embodiments of the Invention The present inventors have conducted studies to solve the above-mentioned problems, and as a result, as shown in Examples described later, monosaccharides were added to buffered aspirin preparations. By mixing at least one compound selected from disaccharides and sugar alcohols, it is possible to obtain an orally disintegrating aspirin-containing tablet having the strength and hardness required for tablets, and having good chewability and disintegration in mouth. And completed the present invention.

That is, the present invention provides (A) aspirin,
Disclosed is an orally disintegrating aspirin-containing tablet comprising (B) an antacid and (C) one or more compounds selected from monosaccharides, disaccharides and sugar alcohols.

The orally disintegrating aspirin-containing tablet may be a multilayer tablet having (A) a layer containing aspirin and (B) a layer containing an antacid and a compound (C). ) An antacid and a compound (C),
It is more preferable that the composition is blended as a granulated product. Further, among the orally disintegrating tablets, it is more useful when used as chewable tablets or troches. Further, the orally disintegrating aspirin-containing tablet, further,
It is more effective to contain (D) a terpenoid compound.

Hereinafter, the present invention will be described in more detail. The orally disintegrating aspirin-containing tablet of the present invention is selected from (A) aspirin, (B) an antacid, (C) a monosaccharide, a disaccharide and a sugar alcohol. Containing a compound. Here, aspirin, which is the component (A) of the present invention, uses a raw material used in a pharmaceutical composition, and the form thereof is either powder or crystal particles composed of a single component, or a granulated substance as described later. Can also be used.

The amount of aspirin in the tablet of the present invention is
It is not particularly limited and can be appropriately selected depending on the size of the tablet and the like, but is usually 5 to 70% (mass%, hereinafter the same), preferably 20 to 6% based on the whole tablet.
It is suitable to be 5%. If the amount is too small, it may be necessary to increase the size of the tablet in order to obtain a sufficient drug effect. If the amount is too large, inconvenience may occur in the formulation design. In the case of the present invention, (A)
A multi-layer tablet having a layer containing aspirin and a layer containing (B) an antacid and a compound (C) is more preferable. In this case, the aspirin in the aspirin-containing layer is used for the same reason as described above. Is suitably 30 to 98%, preferably 80 to 95%, based on the entire layer.

The antacid used as the component (B) of the present invention is not particularly limited, and examples thereof include aminoacetic acid, magnesium silicate, synthetic aluminum silicate, synthetic hydrotalcite, and magnesium oxide. , Dihydroxyaluminum aminoacetic acid (aluminum glycinate), aluminum hydroxide, magnesium carbonate,
Calcium carbonate, magnesium metasilicate aluminate,
Co-precipitated product of aluminum hydroxide / sodium hydrogen carbonate, co-precipitated product of aluminum hydroxide / magnesium carbonate / calcium carbonate, co-precipitated product of aluminum hydroxide / potassium aluminum sulfate, etc. More preferred are magnesium carbonate, dihydroxyaluminum / aminoacetic acid, synthetic hydrotalcite, magnesium silicate, a coprecipitated product of aluminum hydroxide / sodium hydrogencarbonate, calcium carbonate, and the like. These antacids can be used alone or in an appropriate combination of two or more.

The amount of the antacid in the tablet of the present invention is
Although not particularly limited, the mass ratio to the aspirin is usually (A) aspirin: (B) antacid = 1.
It is preferable to mix them in a ratio of 0: 1 to 1: 2, more preferably 3: 1 to 1: 1. When the tablet of the present invention is a multilayer tablet as described above, the compounding amount of the antacid in the layer containing (B) the antacid and (C) the compound is as follows:
10 to 95%, preferably 20 to 60%, based on the whole layer
It is preferable that

The compound to be blended as the component (C) of the present invention is at least one or more selected from monosaccharides, disaccharides and sugar alcohols, and the type is not particularly limited. Monosaccharides such as glucose (glucose) and fructose (fructose); disaccharides such as lactose (lactose) and maltose (maltose); sugar alcohols such as sorbitol, xylitol, erythritol and mannitol And the like.

The compounding amount of the compound (C) in the tablet of the present invention is not particularly limited, but is usually the same as that of the compound (B).
The mass ratio to the antacid is (C) compound: (B) antacid =
10: 1 to 1: 5 is preferred, and more preferably 7: 1 to 1: 1.
The ratio is 2: 5, particularly preferably 6: 1 to 2: 3. In this range, particularly good strength and disintegration can be obtained. As described above, when the tablet of the present invention is a multilayer tablet, the above-mentioned (C) in the layer containing (B) the antacid and the (C) compound is used.
The compounding amount of the compound is suitably 2 to 80%, preferably 5 to 65% based on the whole layer.

The buffered aspirin tablet of the present invention may further contain a terpenoid compound as the component (D) in addition to the above-mentioned components to reduce the bitterness of aspirin and antacid contained in the preparation which rapidly disintegrated in the mouth. Since it can be suppressed well, it is more preferable. Preferred examples of the terpenoid compound include, for example, terpene hydrocarbons such as limonene, camphene, pinene and terpinene, terpene aldehydes such as citral and citronellal, terpene alcohols such as menthol, geraniol, borneol, linalool, and the like. They can be used alone or in combination of two or more.

Here, the terpenoid compound is usually contained in a fragrance compounded as a flavoring agent, and in the case of the present invention, it is preferable to add a fragrance containing such a terpenoid compound, more preferably A fragrance containing at least the terpene hydrocarbon and the terpene aldehyde is preferable.

When the above-mentioned terpenoid compound is blended as a flavor component, the blending amount can be appropriately selected according to the content of the terpenoid compound in the flavor, and the blending amount of the flavor is usually 0.01 to 0.01% based on the total mass of the tablet. ~ 5
%, Preferably 0.05 to 2.5%. If the amount is too large, the taste and aroma of the terpenoid compound may be too strong. If the amount is too small, the effect of the terpenoid compound may not be sufficiently obtained. When the terpenoid compound is blended, if the tablet of the present invention is a multilayer tablet, for example, it may be blended in any layer as long as there is no inconvenience in the formulation due to the blending.

The buffered aspirin tablet of the present invention may further contain, in addition to the above, a dye, which is a commonly used additive, if necessary.
A disintegrating agent, a binder, a lubricant, a flavor, a flavoring agent, and the like can be arbitrarily added as long as the effects of the present invention are not impaired.

The form of the tablet of the present invention is not particularly limited, but is preferably (A) an aspirin-containing layer containing aspirin, (B) an antacid and (C) a monosaccharide, A multilayer tablet having an antacid layer containing a compound selected from disaccharides and sugar alcohols is preferred from the viewpoint of aspirin stability. In this case, the number of layers is not particularly limited, but usually a two-layer tablet or the aspirin-containing layer, the intermediate layer containing the compound (C), the antacid (B) and the compound (C) A three-layer tablet comprising the above-mentioned antacid layer is preferred.

Further, the tablet of the present invention is characterized in that:
The composition of the component (C) is not particularly limited,
As described above, aspirin which is the component (A) may be used as a powder or a crystal particle composed of a single component,
It may be used as a granulated product. Here, when granulating aspirin, ingredients, granulation method and the like are not particularly limited, for example, commonly used corn starch, carmellose, crystalline cellulose, crosslinked polyvinylpyrrolidone, croscarmellose, Mixing with a disintegrant such as partially pregelatinized starch and granulating using a dry granulator is more preferable because the disintegration time can be further reduced. Further, at the time of granulation, a pigment, a fragrance, a flavoring agent, a flavoring agent and the like can be blended. Furthermore, a monosaccharide, a disaccharide, and a sugar alcohol, which are the component (C) of the present invention, can also be blended.

In the tablet of the present invention, the particle size of the granulated aspirin at the time of tableting is preferably from 100 μm to 1500 μm, more preferably from 100 μm to 1000 μm.
Particularly preferably, it is 200 μm to 800 μm, most preferably 300 μm to 600 μm. In this range, there is no adhesion to a tableting machine at the time of production, and the solubility is good. In addition,
Particles having the above particle size range can be obtained by sieving prescribed in the Japanese Pharmacopoeia.

On the other hand, the (B) antacid and the (C) compound can be any of powder, crystal particles, etc., or granules composed of a single component.
The composition containing the antacid and the compound (C) further includes hydroxypropylcellulose, polyvinylpyrrolidone,
It is preferable to add a water-soluble polymer compound such as gelatin and mix it as a granulated product containing a granulated antacid and a saccharide and / or a sugar alcohol. It is more preferable to form a layer containing the (B) antacid and the (C) compound by the mixed granulation of the (B) antacid and the (C) compound.

In this case, the particle size of the granulated product is not particularly limited, but is usually 50 μm to 1000 μm.
It is preferable that the particles are sieved so that particles in the range of 100 μm, preferably in the range of 100 μm to 500 μm are selected and sized.

In the case of the present invention, the particle size of the saccharide or sugar alcohol when granulating the above-mentioned component (C) or tableting as a powder composed of a single component is 1 to 300 μm.
Is preferred, and more preferably 10% or less, more preferably 5% or less, of particles exceeding 300 μm, and 5% or less of particles less than 1 μm. In particular, when used for granulation, it is more preferable to use one having a size of 50 μm or less. If the particle diameter of the component (C) is too large, uniformity of the antacid content may be difficult, or the hardness of the obtained tablet may decrease.

[0030] The tableting method of the present invention is not particularly limited, and can be tableted according to a known method. For example, a tableting pressure of 100 to 3000 kg / cm ² , especially 500 to ²
By tableting at 000 kg / cm ² , a tablet having the strength and hardness required for a tablet and disintegrating rapidly in the mouth can be obtained.

[0031]

According to the present invention, the buffered aspirin tablet rapidly disintegrates and liquefies in the mouth, and can be easily taken without using water. Therefore, the orally disintegrating aspirin tablet of the present invention can be usefully used as a chewable tablet that is easily chewable or as an orally disintegrating tablet such as a troche.

[0032]

EXAMPLES Hereinafter, the present invention will be described more specifically with reference to Examples and Comparative Examples, but the present invention is not limited to these Examples.

Example 1 and Comparative Example 1 The buffered aspirin tablets of Example 1 and Comparative Example 1 having the compositions shown in Table 1 were produced according to the following preparation method. Each raw material was pulverized and sized as necessary.

<Method for Preparing Tablet> (Example 1) Aspirin (2550 g) and corn starch (450 g) were mixed with V
The mixture was placed in a mold mixer V-5 (Tokuju Seisakusho) and mixed for 5 minutes to obtain aspirin granules. Next, 900 g of magnesium carbonate and 150 mannitol
0g into Ribbon Mixer R-5 type
Mix for 5 minutes. 500 g of an aqueous solution obtained by adding 950 g of water to 96 g of hydroxypropyl cellulose was added dropwise, and kneaded for 5 minutes. In a fluidized granulator (SFC-5; Freund Sangyo), dried at 70 ° C, and sized using a sieve.
An antacid-containing granule of 500 μm (granulated material containing an antacid and a sugar alcohol) was obtained. 2040 g of granules and magnesium stearate 10
g into a V-type mixer V-5 (Tokusui Seisakusho)
Mix for minutes. Of an antacid blended granule with aspirin granules of the above using a rotary tableting machine 12HUK (Kikusui Seisakusho) (tablet pressure 6).
40 kg / cm ² ) 9 mm in diameter per tablet, weight 3
A 55 mg bilayer tablet (buffered aspirin tablet) was obtained.

Comparative Example 1 A two-layer tablet (buffered aspirin tablet) was obtained in the same manner as in Example 1 except that crystalline cellulose was used instead of mannitol.

The disintegration, hardness, strength (friability), mastication, and disintegration in the mouth of the buffered aspirin tablets of Example 1 and Comparative Example 1 were evaluated by the following methods. The results are also shown in Table 1.

<Measurement Method of Disintegration> Disintegration was measured by using a disintegration tester described in the Japanese Pharmacopoeia and measuring the time required for all six buffered aspirin tablets to disintegrate according to the disintegration test method of the Japanese Pharmacopoeia. It was measured. Water maintained at 37 ° C. ± 2 ° C. was used as the test solution. In the case of the present invention, it is desirable that the disintegration time by the measurement method is less than 60 seconds, particularly 30 seconds or less.

<Method of Measuring Hardness> Hardness was measured using a Monsanto tablet strength tester according to a conventional method (n =
10). In the case of the present invention, the hardness according to the measuring method is preferably 5 to 10 kg, particularly preferably 6 to 10 kg.

<Method of Measuring Friability> Friability was measured for tablets 20
After the tablet was vibrated for 5 minutes under normal conditions using a vibrator (tablet friability tester), the peeled weight was measured, and the ratio to the total weight of the tablet before vibration was determined. In the case of the present invention, the friability by the measuring method is 1% or less, particularly 0.1%.
It is desirably 6% or less.

<Evaluation Method of Chewability and Disintegration in Mouth> Ten panelists sensory evaluated the chewability (easiness of chewing) and disintegration in the mouth (dissolution in the mouth) of tablets. For each evaluation, each panelist gives a score in a 5-point scale of 1 to 10 points (10 points is the best point) based on their respective standards, calculates the average score of 10 panelists, rounds off the decimal point, and scores 4 points or more. 、 ３: 3 points were evaluated as Δ, and 2 points or less were evaluated as ×.

[0041]

[Table 1]

Example 2 and Comparative Example 2 According to the following preparation method, buffered aspirin tablets of Examples 2 and Comparative Example 2 having the compositions shown in Table 2 were produced, and buffered in the same manner as in Example 1 and Comparative Example 1. The disintegration, hardness, strength (friability), mastication, and disintegration in the mouth of the aspirin tablet were evaluated. The results are also shown in Table 2.

<Method of Preparing Tablet> (Example 2) Aspirin 2550 g, partially pregelatinized starch 150 g,
300 g of xylitol was put into a V-type mixer V-5 (Tokuju Seisakusho) and mixed for 5 minutes. This is a dry granulator (ALE)
(XANDERWEK EINSPEIS type), roll-compressed, and sized to obtain 200-800 μm aspirin granules. Next, 900 g of aluminum glycinate and 1500 g of xylitol were added to Ribbon Mixer R-5 type (Tokuju Seisakusho)
And mixed for 5 minutes. 500 g of an aqueous solution obtained by adding 950 g of water to 96 g of polyvinylpyrrolidone was added dropwise, and 5
Kneaded for minutes. In a fluidized granulator (SFC-5; Freund Sangyo), dried at 70 ° C, and sized using a sieve.
An antacid-containing granule of 500 μm (granulated material containing an antacid and a sugar alcohol) was obtained. 2040 g of granules and 10 g of stearic acid
The mixture was placed in a mold mixer V-5 (Tokuju Seisakusho) and mixed for 3 minutes. Of an antacid blended granule with aspirin granules of the above using a rotary tableting machine 12HUK (Kikusui Seisakusho) (tablet pressure 6).
35kg / cm ² ) 9mm in diameter per tablet, weight 3
A 55 mg bilayer tablet (buffered aspirin tablet) was obtained.

Comparative Example 2 A two-layer tablet (buffered aspirin tablet) was obtained in the same manner as in Example 2 except that a partially pregelatinized starch and hydroxypropylcellulose were used in place of xylitol. .

[0045]

[Table 2]

[Examples 3 to 5] The buffered aspirin tablets of Examples 3 to 5 having the compositions shown in Table 3 were produced according to the following preparation methods. The strength (friability), chewability and disintegration in the mouth were evaluated. The results are also shown in Table 3.

<Method for Preparing Tablet> (Example 3) Aspirin 2550 g, croscarmellose 150
g, lactose 300g, V type mixer V-5 type (Tokuju Seisakusho)
And mixed for 7 minutes. This is a dry granulator (ALEXA)
(NDERWERK EINSPEIS type), roll-compressed, and sized to obtain 200-800 μm aspirin granules. Next, 900 g of Kumlite (trade name, co-precipitated product of aluminum hydroxide and sodium bicarbonate) and 1500 g of erythritol were added to Ribbon Mixer R-5 (Tokuju Seisakusho)
And mixed for 5 minutes. 500 g of a uniform aqueous solution obtained by adding 950 g of water to 96 g of gelatin was added dropwise and kneaded for 5 minutes. In a fluidized granulator (SFC-5; Freund Sangyo), dried at 70 ° C., and sized using a sieve.
The antacid-containing granules (granules containing an antacid and a sugar alcohol) of 500 μm were obtained. 2040 g of granules and magnesium stearate 10
g into a V-type mixer V-5 (Tokushou Seisakusho)
Mix for minutes. Of an antacid blended granule with aspirin granules of the above using a rotary tableting machine 12HUK (Kikusui Seisakusho).
887 kg / cm ² ) to obtain a bilayer tablet (buffered aspirin tablet) having a diameter of 9 mm and a weight of 355 mg per tablet.

Example 4 2550 g of aspirin, 150 g of crospopidone and 300 g of sorbitol were put into a V-type mixer V-5 (Tokuju Seisakusho) and mixed for 6 minutes. This is a dry granulator (ALE)
(XANDERWEK EINSPEIS type), roll-compressed, and sized to obtain 200-800 μm aspirin granules. Next, 900 g of synthetic hydrotalcite and 1000 g of erythritol were put into a ribbon mixer R-5 type (Tokuju Seisakusho) and mixed for 5 minutes. An aqueous solution made uniform by adding 950 g of water to 48 g of hydroxypropylcellulose and 450 g of sorbitol was sprayed and wet-granulated. Is dried at 70 ° C., sized using a sieve,
An antacid-containing granule (granules containing an antacid and a sugar alcohol) having a size of ~ 300 µm was obtained. 2040 g of granules and magnesium stearate 10
g into a V-type mixer V-5 (Tokusui Seisakusho)
Mix for minutes. Of the antacid-containing granules with the aspirin granules of Table 1 using a rotary tableting machine 12HUK (Kikusui Seisakusho).
990 kg / cm ² ) to obtain a bilayer tablet (buffered aspirin tablet) having a diameter of 8 mm per tablet and a weight of 351 mg.

Example 5 2550 g of aspirin, 150 g of crystalline cellulose, 100 g of carmellose, and 200 g of corn starch were placed in a stirring mixer FS10J (Fukae Kogyo) and mixed with a main blade at 120 rpm and a chopper at 1800 rpm for 10 minutes. . This is a dry granulator (ALEXANDERWERK)
Roll compression with EINSPEIS type), sizing and 200
Aspirin granules of ８００800 μm were obtained. Next, 900 g of precipitated calcium carbonate, erythritol 1
000g fluidized granulator (SFC-5; Freund Corporation)
And mixed for 5 minutes. An aqueous solution made uniform by adding 950 g of water to 48 g of hydroxypropyl cellulose and 450 g of sorbitol was sprayed and wet-granulated. Is dried at 70 ° C. for 1 hour, sieved using a sieve,
The antacid-containing granules (granules containing an antacid and a sugar alcohol) having a size of 100 to 300 µm were obtained. 2040 g of granules and magnesium stearate 10
g into a V-type mixer V-5 (Tokushou Seisakusho)
Mix for minutes. Of an antacid blended granule with aspirin granules of the above using a rotary tableting machine 12HUK (Kikusui Seisakusho).
990 kg / cm ² ) to obtain a bilayer tablet (buffered aspirin tablet) having a diameter of 8 mm per tablet and a weight of 351 mg.

[0050]

[Table 3]

The tablets of Examples 1 to 5 were packaged in a PTP made of a cyclic polyolefin material and stored in a paper box.
As a result of confirming the stability of aspirin after storage for 6 months under conditions of 75 ° C. and a relative humidity of 75%,
The aspirin decomposition rates of the tablets of No. 5 were all within 3%.

Further, the tablets of Examples 1 to 5 were put in a sugar-coated pan and a small amount of alcohol (ethanol) was added.
0.2% by mass of the fragrance dissolved in
(0.1% by weight of limonene, 0.05% by weight of menthol,
(Orange oil: 0.05% by mass), sprayed and air-dried, and the flavor was added to the tablets of Examples 1 to 5. Each of these tablets was a particularly good orally disintegrating tablet in which the bitterness and odor of aspirin and the antacid were suppressed.

──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. ⁷ Identification code FI Theme coat ゛ (Reference) A61K 47/06 A61K 47/06 47/26 47/26 F term (Reference) 4C076 AA40 AA49 BB01 CC01 CC05 DD22 DD34T DD38K DD41 DD67K EE30K EE32 FF06 FF27 FF28 FF36 FF52 4C086 AA01 DA17 HA04 HA05 MA02 MA03 MA05 MA35 MA36 MA52 NA02 NA09 NA10 NA11 ZA07 ZA08 ZB11

Claims (5)

[Claims] (A) aspirin, (B) an antacid,
(C) 1 selected from monosaccharides, disaccharides and sugar alcohols
An orally disintegrating aspirin-containing tablet comprising at least one compound. 2. A layer containing (A) aspirin,
The orally disintegrating aspirin-containing tablet according to claim 1, which is a multilayer tablet having the (B) antacid and a layer containing the (C) compound. 3. The orally disintegrating aspirin-containing tablet according to claim 1, wherein a granulated product containing the (B) antacid and the (C) compound is blended. 4. The tablet according to claim 1, which is a chewable tablet or a troche.
4. The orally disintegrating aspirin-containing tablet according to 2 or 3. 5. The orally disintegrating aspirin-containing tablet according to any one of claims 1 to 4, further comprising (D) a terpenoid compound.